TRADE REMEDIES | 2026-08-24
Section 232 Pharmaceutical Tariffs: What California Importers Must Know in August 2026
A 100% tariff on patented branded drugs, biologics, and active pharmaceutical ingredients now reaches most importers, and California life-sciences companies face immediate compliance and cost pressures.
By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published
California pharmaceutical importers, distributors, hospital systems, and life-sciences companies are confronting one of the most consequential trade measures in recent memory. On April 2, 2026, the President issued a proclamation under Section 232 of the Trade Expansion Act of 1962 imposing a 100 percent ad valorem tariff on imports of patented and branded pharmaceutical products, biologics, and their active pharmaceutical ingredients. The measure took effect on a phased schedule: it applied fir
Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.
Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301